ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 0209 • ACR Convergence 2022

    Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis

    Josh Dan1, Grant Sprow2, Josef Concha3, Nilesh Kodali4, DeAnna Diaz5, Thomas Vazquez6, Felix Chin7, Barbara White8 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Albert Einstein College of Medicine, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4New Jersey Medical School, Coppell, TX, 5Philadelphia College of Medicine, Philadelphia, PA, 6FIU Wertheim College of Medicine, Virginia Beach, VA, 7University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 8SFJ Pharmaceuticals, Towson, MD

    Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…
  • Abstract Number: 1383 • ACR Convergence 2022

    Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

    Rebecca Olveda, Jessica Neely and Susan Kim, UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
  • Abstract Number: 1879 • ACR Convergence 2022

    Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies

    jiram torres-Ruiz1, Abdiel Absalón-Aguilar2, Juan Alberto Reyes-Islas2, Alfredo Pérez-Fragoso2, Nancy R Mejía-Domínguez3, guillermo Juárez-Vega4, Alejandro Alfaro-Goldaracena5, Beatriz Alcalá-Carmona2, Guillermo Juárez-Vega3, Fabiola Cassiano-Quezada2 and Diana Gómez-Martín1, 1INCMNSZ, Ciudad de México, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, 5Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

    Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
  • Abstract Number: 0684 • ACR Convergence 2021

    Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy

    Yoshiyuki Abe1, Masahiro Kogami2, Makio Kusaoi2, Kurisu Tada3, Ken yamaji4 and Naoto Tamura3, 1Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo University, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 4Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan

    Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
  • Abstract Number: 0714 • ACR Convergence 2021

    Diagnostic Accuracy of Electromyogram for Myositis

    Lois bolko1, Sarah Leonard Louis2, Jean hugues Salmon1, Olivier Benveniste3, Yves Allenbach3 and Thierry Maisonobe4, 1Rheumatology, CHU maison blanche, Reims, Reims, France, 2Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, 3Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, 4Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France

    Background/Purpose: The skeletal muscle biopsy is the gold standard for idiopathic inflammatory myopathies (IIM) diagnosis. Myositis specific antibodies are diagnostic biomarkers for IIM but are…
  • Abstract Number: 0687 • ACR Convergence 2021

    Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis

    Christopher Mecoli1, Eleni Tiniakou2, William Kelly2, Jemima Albayda2, Julie Paik2, Brittany Adler2, Andrew Mammen3, Cheng Ting Lin1, Sonye Danoff4, Livia Casciola-Rosen5 and Lisa Christopher-Stine2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3National Institutes of Health, Bethesda, MD, 4Johns Hopkins Medicine, Baltimore, MD, 5Johns Hopkins, Baltimore, MD

    Background/Purpose: We describe a single-center North American adult cohort of MDA5-positive DM, with emphasis on the subgroup of patients that experience drug-free long-term remission. Methods:…
  • Abstract Number: 0719 • ACR Convergence 2021

    Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies

    Gözde Kübra Yardımcı1, Arzu Taghiyeva2, Enes Erul2, Bayram Farisogulları3, Levent Kilic1 and Sule Apraş Bilgen1, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2HACETTEPE UNIVERSITY, Ankara, Turkey, 3Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
  • Abstract Number: 0688 • ACR Convergence 2021

    Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis

    Christopher Mecoli1, Takeru Igusa2, Mengkun Chen3, XingYao Wang2, Jemima Albayda2, Julie Paik2, Eleni Tiniakou2, Brittany Adler2, Carrie Richardson4, William Kelly2, Sonye Danoff5, Andrew Mammen6, Elizabeth Platz3, Antony Rosen2, Lisa Christopher-Stine2, Livia Casciola-Rosen7 and Ami Shah8, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins School of Public Health, Baltimore, MD, 4Rush University Medical Center, Chicago, IL, 5Johns Hopkins Medicine, Baltimore, MD, 6National Institutes of Health, Bethesda, MD, 7Johns Hopkins, Baltimore, MD, 8Johns Hopkins Rheumatology, Baltimore, MD

    Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…
  • Abstract Number: 0720 • ACR Convergence 2021

    The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients

    Yuji Hosono1, Azusa Kojima1, Akira Ishii1, Yuto Izumi1, Kazuki Hirano1, Noriko Sasaki2, Chiho Yamada1 and Shinji Sato3, 1Tokai University School of Medicine, Isehara, Japan, 2tokai university, sagamihara-city, Japan, 3Tokai University, Isehara, Japan

    Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
  • Abstract Number: 0689 • ACR Convergence 2021

    Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort

    Vanessa Kronzer1, Bradly Kimbrough2, Cynthia Crowson3, John Davis1, Marie Holmqvist4 and Floranne Ernste1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan & Peter 1975 criteria, and most were not population-based.…
  • Abstract Number: 0756 • ACR Convergence 2021

    Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis

    R Naveen1, Darpan R Thakare2, Vikas Agarwal2, Rohit Aggarwal3 and Latika Gupta1, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
  • Abstract Number: 0695 • ACR Convergence 2021

    Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    Rohit Aggarwal1, Christina Charles-Schoeman2, Joachim Schessl3, Zsuzsanna Bata-Csorgo4, Mazen Dimachkie5, Zoltan Griger6, Sergey Moiseev7, Chester Oddis1, Elena Schiopu8, Jiri Vencovsky9, Irene Beckmann10, Elisabeth Clodi10, Todd Levine11 and and the ProDERM Investigators12, 1University of Pittsburgh, Pittsburgh, PA, 2Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 3Friedrich-Baur-Institut/Medical University Munich, München, Germany, 4University of Szeged, Faculty of Medicine, Szeged, Hungary, 5University of Kansas Medical Center, Kansas City, KS, 6University of Debrecen, Debrecen, Hungary, 7First Moscow State Medical University, Moscow, Russia, 8University of Michigan, Ann Arbor, MI, 9Institute of Rheumatology, Prague, Czech Republic, 10Octapharma PPG, Vienna, Austria, 11Phoenix Neurological Associates, LTD, Phoenix, AZ, 12Different Institutions in several countries, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with characteristic skin rash and muscle weakness. Intravenous immunoglobulin (IVIg) has long been used as adjuvant…
  • Abstract Number: 0766 • ACR Convergence 2021

    Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort

    Jessica Neely1, Kaveh Ardalan2, Adam Huber3 and Susan Kim4, 1University of California San Francisco, San Francisco, CA, 2Duke University Medical Center, Durham, NC, 3Dalhousie University, Halifax, NS, Canada, 4UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
  • Abstract Number: 0696 • ACR Convergence 2021

    Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study

    Lara Dani1, Sandra Selickaja2, Angeles Shunashy Galindo-Feria3, John Svensson4, Paulius Venalis5, Dag Leonard6, Malin Hemberg7, Balsam Hanna8, Ingrid E Lundberg9 and Marie Holmqvist4, 1Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 2State Research Institute for Innovative Medicine and Vilnius university hospital Santaros Klinikos, Vilnius, Lithuania, 3Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Department of Rheumatology, Uppsala University, Uppsala, Sweden, 7Rheumatology Unit, Falu Lasarett, Falun, Sweden, 8Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, 9Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: To longitudinally follow the levels of anti- transcriptional intermediary factor (TIF)1-gamma autoantibodies in patients with dermatomyositis with and without cancer.Methods: We identified sera from…
  • Abstract Number: 0773 • ACR Convergence 2021

    Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis

    Hanna Kim1, Ly-Lan Bergeron2, Samantha Dill2, MIchelle O'Brien2, Xiaobai Li3, Jomy George3, April Brundidge2, Michelle Millwood2, Lisa Rider4 and Robert Colbert5, 1Juvenile Myositis Pathogenesis and Therapeutics Unit, NIAMS, National Institutes of Health, Bethesda, MD, 2Office of Clinical Director, NIAMS, National Institutes of Health, Bethesda, MD, 3Clinical Center, National Institutes of Health, Bethesda, MD, 4NIEHS, NIH, Garrett Park, MD, 5NIH/NIAMS, Bethesda, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology